Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1336 to 1350 of 2188 results for guidelines

  1. Duration of risk of systemic anticancer treatment in people with cancer and COVID-19: Are people who have had SACT recently (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of poor outcomes from COVID-19 compared with those who had SACT less recently?

    Source guidance details Comes from guidance COVID-19 rapid guideline: delivery of systemic anticancer treatments Number NG161

    Research recommendation
    Published
    21 October 2021

  2. Develop and validate new and existing screening tools (including physical, psychological and psychiatric aspects) for post-COVID-19 syndrome in a UK population. What tools are validated for screening for post‑COVID‑19 syndrome, which are the most accurate at identifying post‑COVID‑19 syndrome in a UK population and what is their effectiveness in guiding management?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of COVID-19 Number NG188

    Research recommendation
    Published
    15 November 2021

  3. What effects does isolation have on the quality of life of people being treated for TB?

    to significantly affect a person's quality of life. Despite this, the guideline committee identified no reliable data on the impact of...

    Research recommendation
    Published
    8 November 2019

  4. Prescribing beyond monotherapy:- What is the clinical and cost effectiveness of various ADHD prescribing strategies when monotherapy has failed?

    Any explanatory notes(if applicable) Why is this important:- This guideline makes recommendations for the medication choices for people...

    Research recommendation
    Published
    14 November 2018

  5. QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)

    NICE has developed a medtech innovation briefing (MIB) on QuickChange Incontinence Wrap for urinary incontinence in men .

    Medtech innovation briefing
    Published
    24 November 2020

  6. URO17 for detecting bladder cancer (MIB250)

    NICE has developed a medtech innovation briefing (MIB) on URO17 for detecting bladder cancer .

    Medtech innovation briefing
    Published
    4 February 2021

  7. Lumella point-of-care test for assessing pre-eclampsia risk (MIB287)

    NICE has developed a medtech innovation briefing (MIB) on Lumella point-of-care test for assessing pre-eclampsia risk .

    Medtech innovation briefing
    Published
    1 March 2022

  8. What are the views, preferences and experiences of people with COVID-19-associated pulmonary aspergillosis (CAPA), and their families or carers, on:• available tests for diagnosing CAPA• available treatments for CAPA?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing COVID-19 Number NG191 Date issued March

    Research recommendation
    Published
    9 March 2022

  9. Sorafenib for treating advanced hepatocellular carcinoma (TA474)

    Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.

    Technology appraisal guidance
    Published
    6 September 2017
    View recommendations

    Sections for TA474

  10. What models of service delivery enable intraoperative endoscopic retrograde cholangiopancreatography (ERCP) for bile duct clearance to be delivered within the NHS? What are the costs and benefits of different models of service delivery?

    Any explanatory notes(if applicable) Evidence reviewed for this guideline identified that intraoperative ERCP is both clinically and...

    Research recommendation
    Published
    9 June 2015

  11. Subcutaneous methotrexate:- What is the clinical and cost effectiveness of subcutaneous methotrexate compared with oral methotrexate for adults with early onset RA starting a new DMARD?

    with oral drugs. Research on subcutaneous methotrexate will inform future guideline recommendations. Source guidance details Comes from...

    Research recommendation
    Published
    11 December 2018

  12. Red blood cell transfusion thresholds for patients with chronic cardiovascular  disease:- What is the clinical and cost effectiveness of restrictive compared with liberal red blood cell thresholds and targets for patients with chronic cardiovascular disease?

    thresholds in populations with coronary ischaemia at baseline. In this guideline a level of 80–100 g/litre was used for patients with...

    Research recommendation
    Published
    11 December 2015

  13. Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)

    Evidence-based recommendations on mavacamten (Camzyos) for symptomatic obstructive hypertrophic cardiomyopathy.

    Technology appraisal guidance
    Published
    6 September 2023
    View recommendations

    Sections for TA913

  14. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for plaque psoriasis in children and young people.

    Technology appraisal guidance
    Published
    12 July 2017
    View recommendations

    Sections for TA455

  15. Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)

    Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA406